---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-048997"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T04:09:19.054765+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares

## Summary
- Dr. Daniel Gilmer (39) appointed to Board effective April 24, 2026.
- He will receive an option award to purchase 51,280 shares vesting over three years.
- Non-management directors receive a cash retainer of $40,000 per year.
- Gilmer is Senior Director at Pfizer and led the U.S. launch of PAXLOVID.
- He is co-inventor of Streptococcus phage lysin exebacase (CF-301).

## SEC filing metadata
- accession: 0001104659-26-048997
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926048997/0001104659-26-048997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926048997/tm2610924d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-048997
- JSON: https://secwatch.observer/filing/0001104659-26-048997.json
- Plain text: https://secwatch.observer/filing/0001104659-26-048997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.